secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-04-28T23:59:59+00:00
Accession:  0001437749-23-011514
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics reports positive Phase 3 results for SAB-185 in high-risk COVID-19 patients
--------------------------------------------------------------------------------

- 66% of SAB-185 patients reached sustained symptom resolution by Day 28 vs 50% for REGEN-COV (p=0.010).
- Median time to symptom resolution was 7 days shorter for SAB-185 vs REGEN-COV (p=0.010).
- Primary endpoint (hospitalization/death) inconclusive due to low events after Omicron emergence.
- Grade 3+ adverse event rates similar between SAB-185 and REGEN-COV arms.
- SAB-176 for influenza granted Fast Track and Breakthrough Therapy designations from FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923011514/0001437749-23-011514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923011514/sabs20230427_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-011514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer